The North America Digital Diabetes Management Market is experiencing substantial growth owing to technological advancements and rising incidence of diabetes. The market size was valued at USD 5,700 Million in 2025 and is expected to reach USD 17,400 Million by 2035, growing at a CAGR of 10.8% from 2024 to 2035.
The economic impact of tariffs on "North America Digital Diabetes Management Market".
Market Growth Drivers
Adoption of Connected Devices and Integration with Healthcare Ecosystems: Leading companies such as Medtronic and Dexcom have introduced advanced connected devices like Continuous Glucose Monitors (CGMs) and smart insulin pens. These devices are equipped with real-time data transmission capabilities, allowing seamless integration with electronic health records (EHRs) and mobile applications. The interoperability and connectivity are driving higher acceptance among patients and healthcare professionals, leading to improved glycemic control through timely interventions. This trend is further supported by partnerships between device manufacturers and digital health platforms for real-time remote monitoring.
Rising Demand for Personalized Diabetes Management Solutions: Companies like Abbott and Omada Health are pioneering digital therapeutic programs tailored to individual patient profiles. Personalized digital solutions utilize artificial intelligence and machine learning algorithms to customize treatment recommendations, dietary plans, and medication reminders. These innovations enhance patient engagement and adherence, thus delivering better clinical outcomes. The growing prevalence of Type 2 diabetes and the need for long-term self-management options is accelerating the shift towards digital, patient-centric solutions.
Market Trends
Expansion of Mobile Health (mHealth) Applications: The proliferation of smartphone applications for diabetes management is a significant trend. Companies like One Drop and mySugr offer comprehensive mHealth platforms that track blood glucose levels, physical activity, nutrition, and medication. These platforms provide users with actionable insights and have led to improved disease monitoring and patient empowerment. Integration with wearable tech and smart devices further strengthens real-time tracking and data sharing between patients and caregivers.
Emergence of AI-Driven Predictive Analytics: Digital diabetes management solutions are increasingly incorporating artificial intelligence for predictive analytics. Livongo (acquired by Teladoc Health) utilizes AI to deliver predictive alerts and personalized coaching for people with diabetes, enabling proactive intervention before adverse events occur. This trend is enhancing preventive care and reducing hospital admissions, which is especially important amid rising healthcare costs and a greater focus on value-based care models.
Market Opportunities
Integration with Telehealth for Comprehensive Chronic Disease Management: The acceleration of telehealth adoption presents an opportunity for digital diabetes management platforms to offer holistic care services. Companies like Glooko are expanding their digital health platforms to incorporate remote consultations, prescription management, and behavioral counseling, delivering an all-in-one ecosystem that supports improved patient outcomes.
Growth in Artificial Intelligence-Powered Clinical Decision Support: As AI algorithms mature, they present opportunities for real-time clinical decision support integrated within digital diabetes management platforms. This can allow physicians to develop precise therapy plans based on large-scale patient data analysis, driving better clinical outcomes and operational efficiency for healthcare providers.
North America Digital Diabetes Management Market Revenue (USD Million) (2020-2035)
Between 2020 and 2035, the North America Digital Diabetes Management Market is poised for robust expansion. In 2020, the market size stood at USD 3,200 Million, driven by pandemic-induced remote care needs and growing awareness about digital health. By 2025, the market value is projected at USD 5,700 Million, reflecting widespread adoption of connected diabetes management solutions. The upward growth trajectory continues, reaching USD 17,400 Million by 2035, fueled by technological breakthroughs such as AI-enabled analytics, increased utilization of telehealth, and expansion of personalized digital therapeutics. The revenue growth pattern depicted in the chart illustrates a steady compound annual growth rate, highlighting continued market demand and innovation.
North America Digital Diabetes Management Market Share by Region (%) - 2025
The 2025 market share analysis shows the United States leading with a 75% share, reflecting its advanced healthcare infrastructure, high prevalence of diabetes, and greater adoption of digital health technologies. Canada follows at 17%, benefitting from government-backed diabetes management initiatives and rising technology adoption rates. Mexico holds 5%, as digital health investments increase but face infrastructure challenges. The remaining 3% is distributed among other North American territories and Caribbean nations. The pie chart underscores the dominant position of the U.S., with notable growth prospects for Canada and Mexico as digitalization efforts ramp up.
Recent Developments (Last 6 Months)
In March 2024, Dexcom launched the G7 Continuous Glucose Monitoring System in North America, offering enhanced accuracy, a redesigned wearable sensor, and direct connectivity with smartphones and smart watches. The rapid deployment aligns with growing demand for remote patient monitoring and is expected to strengthen Dexcom's market leadership by delivering improved patient experience and advanced data analytics.
Omada Health, in April 2024, announced a strategic collaboration with Teladoc Health to integrate digital diabetes management with telemedicine consultations. This integration allows users to seamlessly transition from remote monitoring to live virtual consultations and prescription refills, driving new standards for continuity of care and increasing patient retention on digital platforms.
Abbott received FDA approval for its Libre Sense, a consumer-facing biosensor designed specifically for non-diabetic glucose monitoring applications in sports and wellness, in May 2024. This expansion into adjacent markets is anticipated to drive new revenue streams, foster product innovation, and enable Abbott to broaden its base beyond traditional diabetes patients.
Press Releases